Search

Endometrial carcinoma is one of the most frequent women cancer. Its incidence is increasing due to the aging of the population and changes in life. Fortunately, these cancers are usually detected at an early stage due to post-menopausal bleeding. The prognostic factors are quite well determined : loco-regional and distant tumoral extension according to the FIGO classification, grade and histological type and the presence of lympho-vascular space invasions. These cancers, however, are usually of good prognosis because of an early diagnosis, and their treatment is based on surgery, preferably minimally invasive approach, whose extension is adapted to the prognostic factors from the pre-therapeutic assessment. The definitive histological examination will condition the adjuvant treatments., Competing Interests: Les auteurs n’ont declare aucun conflit d’interets en relation avec cet article.

The primary treatment of ovarian cancer consists in a complete surgical debulking followed by adjuvant chemotherapy combining platinum with taxanes. Despite this treatment, patient survival has remained stable over the last 20 years. Recently, advances in the sequence, regimens, and route of administration of treatment have enhanced effectiveness and reduced toxicity. Targeted anti-angiogenic therapy and recently PARP inhibitors are now complementing standard treatment and have improved patient progression-free survival. The development of immunotherapy, alone or in combination, brings new perspectives for the future treatment of ovarian cancer., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

Endocrine therapy remains a mainstay in the treatment of endocrine-sensitive breast cancer. In the adjuvant setting, 5 years of endocrine therapy significantly reduces recurrence rate and mortality. Tamoxifen is the molecule of choice for premenopausal women, whereas for postmenopausal women aromatase inhibitors are currently part of the standard treatment. Endocrine therapy can induce side effects, which can affect patient's quality of life and lead to premature treatment interruption. Identification and adequately addressing these side effects is fundamental to maintain good treatment compliance and therefore improve breast cancer specific outcome.